Canaccord raised the firm’s price target on Stryker (SYK) to $435 from $420 and keeps a Buy rating on the shares. The firm said they delivered an impressive Q4, beating on the top and bottom lines and continuing to note healthy capital demand and procedure volumes. They said the company is firing on all cylinders as it continues to innovate, having launched Mako spine and now shoulder applications on time and continuing to benefit from its “super cycle” of new products, with its Pangea plating system ongoing launch and Lifepak35 defibrillator seeing a strong order book as sales ramp.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker Corp Announces Robust 2024 Sales Growth
- Closing Bell Movers: F5 Networks soars to all-time highs on Q1 beat
- Stryker Announces CFO Transition Effective April 2025
- Stryker to sell U.S. spinal implants business to Viscogliosi Brothers
- Stryker CFO Glenn Boehnlein to retire, Preston Wells to succeed
Questions or Comments about the article? Write to editor@tipranks.com